Letter
Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy

https://doi.org/10.1016/j.anai.2021.01.006Get rights and content

Cited by (0)

Disclosures: Dr Howarth reports employment by GlaxoSmithKline. The remaining authors have no conflicts of interest to report.

Funding: The authors have no funding sources to report.

View Abstract